

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	9060822
<b>Application Number:</b>	09451641
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	9327
<b>Title of Invention:</b>	CELECOXIB COMPOSITIONS
<b>First Named Inventor/Applicant Name:</b>	Danchen Gao
<b>Customer Number:</b>	28523
<b>Filer:</b>	Arthur Dean Olson/Kelly Smith
<b>Filer Authorized By:</b>	Arthur Dean Olson
<b>Attorney Docket Number:</b>	PC10664
<b>Receipt Date:</b>	17-DEC-2010
<b>Filing Date:</b>	30-NOV-1999
<b>Time Stamp:</b>	12:44:00
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$180
RAM confirmation Number	11884
Deposit Account	161445
Authorized User	
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)	

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Transmittal Letter	PC10664A-Supplemental_IDS.pdf	31915	no	1
			d1a9d33a098cdadd15c91bd0829433f5934d5b1d		
Warnings:					
Information:					
2	Information Disclosure Statement (IDS) Filed (SB/08)	PC10664A-Supplemental_IDS_Citation.pdf	145007	no	4
			68a164f715531be06219c0aa025df0b6b02a3b014		
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
3	Foreign Reference	EP0488856B1.pdf	5611769	no	23
			8e032efc13d836599c744bdc968b26130a8d0df		
Warnings:					
Information:					
4	Foreign Reference	WO0048583.pdf	1291708	no	7
			414794448b3cd1173124080fedfd946814d0d		
Warnings:					
Information:					
5	NPL Documents	Nature-367-215-216.pdf	1096799	no	2
			8e9eb51d5a83d49b4218612bac5059e395a9fc1		
Warnings:					
Information:					
6	NPL Documents	Drug_News_and_Perspectives-7_501-512.pdf	4606782	no	12
			e59073ccac520888d1863c2c952f128976dbac7		
Warnings:					
Information:					
7	NPL Documents	Tucker_Declaration.pdf	3399300	no	21
			04a42547d1e777fb469bdc15e53cca13d03821c4		
Warnings:					
Information:					
8	NPL Documents	Rompp_Cemi_Lexikon.pdf	1373231	no	4
			b3f50a3f6cc11bd0534d0d624e575d8d86a0a28a		
Warnings:					
Information:					

9	NPL Documents	J_Pharm_Pharmaceut_Sci-6_20-5210.pdf	1630583 9c5c76a4d12cd0f1378ba3b78ccbd4bae080019c	no	6
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	Pharmaceutical_Research-21_201-230.pdf	9075973 b7b6321f6fd5cafa1f12ea3fe68ac9046ee289	no	30
<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	Drug_Bioavailability_207-209.pdf	589625 e47b795008d871d8c31a7e8c8d949ff6ee1445	no	3
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	Clin_Pharmacokinet-39_225-242.pdf	5105105 731abde17720ae73d8f1b1d1f728f4469a3a2d2	no	18
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	Barnett_International.pdf	2877173 2d1458617ac322b8f8baa0e21dc855c74315	no	6
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	PSG_Technical_Conference.pdf	1777542 cb8ff622c66aef8b13a4c3d5af6f7b9fbcd2d5e	no	8
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	Experimental_Protocol.pdf	744598 3cabaf65702cb84be971854ff8ed9d3feaf02c779	no	5
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	Exp_Opin_Pharmacotherapy-2_139-152.pdf	4775055 304c7a840cb78b22ad51d1fb250784ce98cdab06e	no	14
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	Davies_Declaration.pdf	3080285 d07b826f3b52e8722cedc2f6133c9b4d6dd5174	no	18
<b>Warnings:</b>					
<b>Information:</b>					

18	NPL Documents	Taskin_Declaration.pdf	619640 6509391c4d78ec2e688675748013155b689ca358	no	3
Warnings:					
Information:					
19	NPL Documents	Kesten.pdf	3275983 654dc4081b3867d63d61a3e1d4f7fc9d62b359	no	20
Warnings:					
Information:					
20	NPL Documents	Clinical_Trial_Protocol_N49-95-02-006.pdf	15394113 321fcbe8268e1a28628367762efc7d74f16d579	no	87
Warnings:					
Information:					
21	NPL Documents	Internal_Pfizer_Document.pdf	1128358 5d544dbcb60228c4d747f93cef18a31796aa63a9	no	8
Warnings:					
Information:					
22	NPL Documents	Consultant_Agreement.pdf	1253119 27269f5fb2dc8f7791768a48be53515d9f99ae5	no	6
Warnings:					
Information:					
23	NPL Documents	Pharm_Development_and_Technology-3_153-161.pdf	1823871 7e19f5c2ea79869070e7034d0c4e8c481a54d8	no	9
Warnings:					
Information:					
24	NPL Documents	Pharmaceutical_Dosage_Forms_Vol2.pdf	728026 04a16da89998a6fd14d3a31a5d3d698ba45bf2bc	no	4
Warnings:					
Information:					
25	NPL Documents	Proc_R_Soc_Lond-419-137-149.pdf	2585126 6e9843ba3606e3e0673d3e491be97c3009c4d6ae5	no	13
Warnings:					
Information:					
26	NPL Documents	Benita_affidavit_1_Israel_opposition.pdf	2555284 d675d8d1f5c42db41c4b65af3b96a6f13d33c22e	no	10
Warnings:					
Information:					

27	NPL Documents	Benita_affidavit_2.pdf	24538680 30017a1a6f8349d4833c3c6bd4f5a58a6749c8	no	73
Warnings:					
Information:					
28	NPL Documents	bolivia_opposition.pdf	765883 ea2dd2e74df884580fb370b4a6a7d60c141a1e9f	no	3
Warnings:					
Information:					
29	NPL Documents	Colombia_rejection.pdf	1976175 d27f4b123b75c2a86a48de509d22852b5c0098	no	10
Warnings:					
Information:					
30	NPL Documents	Costa_Rica_rejection_overcome_later.pdf	1080257 a43e134584b194cd37a2387d5440826d6c1be8a5	no	16
Warnings:					
Information:					
31	NPL Documents	Cynthia_Webb-Israel-affidavit1.pdf	2430592 2ec85d044dc0b1b67cda2c52d8dac2983b9aa	no	10
Warnings:					
Information:					
32	NPL Documents	Danon_affidavit1_Israel_opposition.pdf	2605383 33ee1973e85d43a37f82b0361518eae5c4b95d	no	8
Warnings:					
Information:					
33	NPL Documents	Danon_affidavit2_Israel-Opposition.pdf	18580301 33054f8cc05377d42be617eaf4ba22bafae1cd4	no	57
Warnings:					
Information:					
34	NPL Documents	Ecuador_opposition.pdf	1358692 9707f25d70aa13d5a725275d6d230335578ee72ab	no	5
Warnings:					
Information:					
35	Foreign Reference	EPO_Appeal_decision.pdf	9734667 cba49672e8356f9187196d9f66175da6da5b5d66	no	58
Warnings:					
Information:					

36	NPL Documents	EPO_Opposition_decision.pdf	5399494 0a1747e7fe7781de3a576c6825619d2916c3db9	no	27
<b>Warnings:</b>					
<b>Information:</b>					
37	NPL Documents	EPO_oppositions.pdf	10952421 91fcd83f32d9a855663ba5c9645e6cbcb7daf1a1ff	no	60
<b>Warnings:</b>					
<b>Information:</b>					
38	NPL Documents	Estonia_Opposition.pdf	3858837 00ba388a43b7d5a25da6e1d13304ba83440a48819	no	12
<b>Warnings:</b>					
<b>Information:</b>					
39	NPL Documents	Eurasian_opposition.pdf	2217576 5ba9f0c47adfed0e0b31eab3146efc0f0c5a3a7d	no	9
<b>Warnings:</b>					
<b>Information:</b>					
40	NPL Documents	Davies_AffidavitandReferences-Guatemala.pdf	14634100 87f9b47ccff177843c5a709cccd08a095db2a17	no	123
<b>Warnings:</b>					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
<b>Information:</b>					
41	NPL Documents	Guatemala-Final_Decision.pdf	3211249 d703303205470b3ab4e24131bc998b652945ba9	no	14
<b>Warnings:</b>					
<b>Information:</b>					
42	NPL Documents	Guatemala-Rejection-June_2003.pdf	472457 75566189b6cd0b89991920a42e8e8c8c3082025	no	2
<b>Warnings:</b>					
<b>Information:</b>					
43	NPL Documents	Guatemala-Response_To_Examiner_Rejection.pdf	1977626 788bc98455cdc5b291a9b15137c34178bc97910a	no	6
<b>Warnings:</b>					
<b>Information:</b>					
44	NPL Documents	Guatemala_Submission-April_2004.pdf	5337623 4eb9e65d34202c1ba97ba2771f96188a10ddb15	no	31

Warnings:					
Information:					
45	NPL Documents	Isreal_Opposition_Summations.pdf	8139866	no	55
Warnings:					
Information:					
46	NPL Documents	Opposition_Decision-Isreal.pdf	7159991	no	26
Warnings:					
Information:					
47	NPL Documents	Philippines-Set_Aside_Refusal.pdf	17773917	no	67
Warnings:					
Information:					
48	NPL Documents	Israel-Notice_of_Appeal.pdf	9257696	no	44
Warnings:					
Information:					
49	NPL Documents	Davies_declaration-Israel_Opposition.pdf	4366306	no	28
Warnings:					
Information:					
50	NPL Documents	Venezuela-Response.pdf	2630191	no	9
Warnings:					
Information:					
51	NPL Documents	Peru-Annulment_Action.pdf	10523456	no	37
Warnings:					
Information:					
52	NPL Documents	Polpharma_Appeal-Poland.pdf	1695156	no	8
Warnings:					
Information:					
53	NPL Documents	Zentiva-Appeal-Poland.pdf	3654677	no	16

Warnings:					
Information:					
54	NPL Documents	Slovak-decision.pdf	6795685 3c44c28db6ffc3bc51801e9a3b01a76d65301d16	no	22
Warnings:					
Information:					
55	NPL Documents	Slovak-Nullity_action.pdf	2816708 2b5dbf98c9f6fd6d20527e791ddad51faf8b353ae7	no	12
Warnings:					
Information:					
56	NPL Documents	Teva-Opposition_Arguments-Isreal.pdf	936338 58f6c0ba290ae134754a2178010796434f6d5	no	6
Warnings:					
Information:					
57	NPL Documents	Turkish_Opposition-Fako.pdf	243729 7ef9b69514eb1098ba3ba67c254d23436563ffae5	no	2
Warnings:					
Information:					
58	NPL Documents	Turkish_Opposition-Oner.pdf	257323 118d6412131053d650ff8b9c1698c17d9e66737	no	2
Warnings:					
Information:					
59	NPL Documents	Turkish_Opposition-Tum.pdf	667335 1cb547f8bd57b63d65abec007db5c8ba5e3d4c2d	no	3
Warnings:					
Information:					
60	NPL Documents	Turkish_Opposition-Nobel_IIlac.pdf	701890 262d0d587f6cd8c22a6f5eb0c57039d55856311a	no	4
Warnings:					
Information:					
61	Fee Worksheet (PTO-875)	fee-info.pdf	30224 d9aa13d628b0d61d4d69c0cb028c75aec2976128	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			265358471		



This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.